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Abstract
Background: Pregnant women were excluded from clinical trials until the 1990s, but the Food and Drug Administration
nowadays allows - and even encourages - responsible inclusion of pregnant women in trials with adequate safety
monitoring. Still, randomized trials in pregnant women face specific enrolment challenges. Previous studies have
focused on barriers to trial participation in studies that had failed to recruit sufficient participants. Our aim was to
identify barriers and motivators for participation in a range of clinical trials being conducted in the Netherlands,
regardless of recruitment performance.
Methods: We performed a qualitative case control study in women who had been asked in 2010 to participate in one
of eight clinical trials during pregnancy or shortly after giving birth. Both participants and non-participants of these
clinical trials were invited for a face-to-face interview that addressed motives for participation and non-participation. We
started the interview in an open fashion, asking the women for their main motive for participation or non-participation.
When no new information emerged in this open part, we continued with a semi-structured interview, guided by a
topic list. Transcripts of the interviews were analysed using a constant-comparative approach. Two researchers
identified barriers and facilitators for participation, conjoined into main themes.
Results: Of 28 women invited for the interview, 21 agreed to be interviewed (12 participants and 9 non-participants).
For 5 of the 12 participants, contribution to scientific research was their main motive, while 5 had participated because
the intervention seemed favorable and was not available outside the trial. Key motives for non-participation (n = 9)
were a negative association or a dislike of the intervention, either because it might do harm (n = 6) or for practical
reasons (n = 3). Combining the open and topic list guided interviews we constructed seven main themes that
influence the pregnant women’s decision to participate: external influence, research and healthcare, perception own
situation, study design, intervention, information and counselling, and uncertainty.
Conclusions: Among seven main themes that influence pregnant women’s decision to participate, uncertainty about
scientific research or the intervention was reported to be of considerable importance. Measures should be taken to
habituate pregnant women more to scientific research, and further evaluation of opt-out consent deserves attention.
Background
Until the 1990s, pregnant women were often excluded
from clinical trials for their own protection [1]. However,
in general pregnancy does not prevent a women from
acquiring a disease or cure a women from a disease.
Pregnant women may even be more severely affected,
for example by infectious diseases [2]. Paradoxically, the
efforts to protect the fetus from research-related risks by
excluding pregnant women from research places both at
risk from unstudied interventions [3, 4].
In the United States approximately 2 in 3 pregnant
women are given prescription medication during preg-
nancy [2]. These prescriptions are often based on limited
evidence on safety or effectiveness, as results of studies
in non-pregnant women may not always apply to preg-
nant women. The Food and Drug Administration now-
adays allows – and even encourages – responsible
inclusion of pregnant women in drug trials with ad-
equate safety monitoring [5].
Randomized trials in pregnant women still face spe-
cific enrolment challenges. Such studies are unique,
* Correspondence: K.OudeRengerink@amc.uva.nl
Katrien Oude Rengerink and Sabine Logtenberg share first authorship.
1Academic Medical Center, Department of Obstetrics and Gynaecology,
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 Oude Rengerink et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Oude Rengerink et al. BMC Pregnancy and Childbirth  (2015) 15:207 
DOI 10.1186/s12884-015-0641-x
since two patients are involved: the mother and her un-
born fetus. A woman may refuse treatment for herself if
she feels this could harm her baby, or she may feel
bound to accept interventions that might benefit the
fetus. Additionally, the father’s feelings may also influ-
ence decision-making about trial participation [6].
Tooher and colleagues have presented a narrative re-
view on factors influencing recruitment for maternal and
perinatal trials in which they identified four participant
factors that influence recruitment: understanding risk,
recruitment process and procedures, participants’ under-
standing of the research process and methodological is-
sues, and patient characteristics [7]. Their conclusions
were based on a limited number of studies on maternal
and perinatal trials, often selected because recruitment
was problematic. It is therefore uncertain to what extent
these results also apply to other studies.
We performed a qualitative study to identify the main
barriers and motivators for enrolment in obstetrical




We performed a qualitative case–control study. Women
invited to one of eight clinical trials during or shortly
after pregnancy were invited for a face-to-face interview
about their main motives in accepting or declining the in-
vitation to participate. This study is part of the IMPACT
project, in which enrolment of patients in trials is studied
at different levels [8]. Our study did not require formal ap-
proval of an ethics committee, according to Dutch law, as
confirmed by the ethics committee of the Academic
Medical Center and the Onze Lieve Vrouwe Gasthuis in
Amsterdam. Written informed consent was obtained for
all face to face interviews, and verbal consent was ob-
tained for telephone interviews.
Selection of trials and interviewees
We invited 28 women who had been invited for a clin-
ical trial in obstetrics up to three months prior to the
interview . We selected in a 1:1 ratio women who had
accepted and women who had declined enrolment.
Women were selected from eight multicenter studies
running in the Consortium for Women’s health and
Reproductivity that recruited patients between February
and June 2010: Allo [9], Apostel I [10], Apostel II [11],
Chips [12], WOMB [13], Ppromexil [14], Hypitat2 [15],
and ProTwin trial [16] (Table 1).
We started by inviting the women most recently in-
vited for a trial, and thereafter selected women less re-
cently invited consecutively (up to 3 months prior to the
interview). Women were only eligible if they were still
pregnant or their baby was born alive and if they could
speak Dutch well enough to participate in the interview
without an interpreter. We first sent an invitation letter
on behalf of the treating gynaecologist and the inter-
viewer introducing the study and the purpose of the
interview. The letter indicated that participation or non-
participation in the interview was completely voluntary
and would not influence their relationship with the
treating physician or her treatment in any way. We an-
nounced to the women that we would try to contact
them by phone about a week after having received the
letter, to give additional explanation and answer any
remaining questions. At least four attempts to reach the
women by phone were made. If she indicated she was not
interested and did not want any additional information
her wishes were respected, and reminders were not sent.
The interview
The interview was conducted face-to-face, unless the re-
spondent explicitly requested a telephone interview, or
when the travel time to visit the patient was 2 h or more.
The interview took place at the patient’s home or in the
hospital, whichever was preferred by the interviewee. An
interview in the hospital was proposed as the hospital
could be perceived as a location were women feel com-
fortable talking about trial participation, as they might
feel uncomfortable inviting the interviewer to their
homes, but it could also be because women or their
newborns were still admitted.
We started the interview in an open fashion, by asking
the women for their main reason for participating or not
participating in the trial. Once no new information
emerged from the open questioning, we continued with
a semi-structured interview guided by a topic list, to
cover all aspects that might have contributed to the de-
cision making process.
The topic list was developed based on a literature re-
view and with input from experienced gynaecologists
and midwives (Additional file 1: Appendix 1, Dutch). It
included factors related to personal benefit, altruism,
knowledge and information about the trial and the trial
process, distrust, attitude, organisational aspects and influ-
ence of the social environment. If new topics emerged dur-
ing the interview, they were added to the topic list [17, 18].
All interviews were recorded and transcribed. Parti-
cipants were asked for verbal consent for audiotaping,
after verbal consent was given the audiotape was started.
We informed the women that whenever they felt un-
comfortable during the interview, they were permitted
to stop the interview at any time, even for no reason.
The transcript was sent to the interviewees to confirm
correctness and completeness (member check). If the
women indicated that the interview was not a good re-
flection of their motives or they did not want their infor-
mation to be used any longer, the information was not
Oude Rengerink et al. BMC Pregnancy and Childbirth  (2015) 15:207 Page 2 of 11
used. All transcripts were coded using one letter of the
alphabet, with the code only known to the interviewer
and transcriber (SL and KOR). Transcripts were not
shared with their treating physician.
We estimated that an interview with about 10 women
in both groups would be needed to reach data saturation,
based on previous papers published [8]. We planned to
perform two additional interviews when data saturation
was reached.
Analysis
The aim of the analysis was to group the content of the
interviews into main themes. Analysis was performed
according to the taxonomy of Strauss & Corbin (‘create
theory out of data’), where one starts with line-by-line
open coding of all relevant phrases of barriers or
motivators for participation (open coding), using a con-
stant comparison method: newly gathered data are con-
tinually compared with previously collected data and
their coding, in order to refine the development of the-
oretical categories [18].
After open coding, the codes were grouped into cate-
gories (axial coding), and then into themes (selective
coding) [18]. All transcripts were reread and recoded,
using the refined coding structure. A fragment was placed
into all relevant categories. Two researchers (SL and KOR)
independently analysed the first seven interviews, there-
after one researcher marked barriers and facilitators, which
was checked by a second researcher. Discussion was
resolved by consensus if needed. For the purpose of this
article direct quotes from the interview were translated by
a professional translator, after analyses had been finished.
Table 1 Overview of the eight trials from which patients were selected for an interview
Trial acronyma Research question Treatment arms Eligible women
Allo [9] Does antenatal allopurinol administration
reduce hypoxic-ischaemic encephalopathy
in neonates exposed to intra-uterine
asphyxia?
Allopurinol or placebo, antenatal
administered to the mother
Women at term in whom the fetus is
suspected of intra-uterine asphyxia
Apostel I [10] Is testing for fibronectin a cost-effective
strategy that prevents unnecessary
treatment in women with threatened
preterm labour?
Tocolytics (nifedipine) or placebo Patients with symptoms of preterm
labour, and a negative fibronectin
test and a cervical length between
10–30 mm
Apostel II [11] Does sustained tocolysis in women with
threatened preterm labour reduce
neonatal morbidity?
Nifedipine or placebo for 12 days Women between 24 to 31+6 weeks
pregnant who have been treated with
tocolysis and steroids for preterm birth
for 48 h
CHIPS [12] Is there a difference on pregnancy loss
or NICU admission between less tight
and tight control of blood pressure in
women with non-severe non-proteinuric
pre-existting hypertension or gestational
hypertension remote from term?
‘less tight’ dBP control or ‘tight’ dBP
control
Women with non-severe non-proteinuric
pre-existing hypertension or gestational
hypertension remote from term
Hypitat II [15] What is the effectiveness and efficiency
of induction of labour in women with
pregnancy induced hypertension or mild
preeclampsia with a gestational age of
34–37 weeks of pregnancy, as compared
to expectant management under regular
monitoring?
Induction of labor or expectant
management under regular
monitoring
Women with pregnancy induced
hypertension or mild preeclampsia with
a gestational age of 34–37 weeks of
gestation
Ppromexil [14] What is the effectiveness and cost-
effectiveness of induction of labor after
PPROM between 34 and 37 weeks
gestation compared to expectant
monitoring.
Induction of labor or expectant
monitoring
Pregnant women with preterm
premature rupture of membranes
between 34 + 0/7 weeks to 37 weeks of
gestation
ProTWIN [16] Is prophylactic use of a cervical pessary
effective in the prevention of preterm
delivery and the neonatal mortality and
morbidity resulting from preterm
delivery in multiple pregnancy?
Pessary or no treatment All women presenting with a multiple
pregnancy between 12–20 weeks of
gestation
WOMB [13] What is the effect of RBC transfusion on
health related quality of life?
RBC transfusion or no intervention Women with PPH or a decrease in Hb,
12 to 24 h after delivery or caesarean
section.
aMore information about these studies can be found at: www.studies-obsgyn.nl
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Results
Interviewees
Of the 28 identified women, four women could not be
reached by phone, two non-participants declined an
interview, and one woman initially consented but was
admitted to hospital for emergency care. Her interview
was cancelled. Twenty-one interviews were performed
(12 with trial participants and 9 with non-participants),
of which 17 were face-to-face and 4 were by phone. The
interview took on average about half an hour. After tran-
scription of the recorded interview, 20 interviewees ap-
proved its content, while one woman did not respond.
Characteristics of the interviewees are shown in Table 2.
Five women had been invited to this study more than
three months after being invited to a trial, mostly due to
incomplete registration of non-participants. All respon-
dents stated they remembered the situation that was dis-
cussed in the interview very well, which we confirmed
during the interviews. We considered data saturation
reached, as no new motives were mentioned during the
last two interviews. As we sampled participants from
different studies, we defined data saturation as no new
motive emerging over all studies. For example, we con-
sidered ‘distrust in the effectiveness of a new interven-
tion’ as a motive, whether this was a pessary in the
ProTwin trial or iron tablets in the Womb study.
Main motive for trial participation or non-participation
The main motives for trial participation as mentioned by
the women are shown in Table 3. Contribution to scien-
tific research was for 5 of the 12 participants their main
motive for participation in the trial, sometimes condi-
tional upon other motives (J, L, T, U, Z). Five par-
ticipants mentioned to have participated because the
intervention seemed favorable and was not available out-
side the trial (M, P, Q, V, W). One woman thought an
extra test could only have positive effects, as ‘there is no
harm in trying’ (N). For one women the reason was not
very clear, she most probably meant to be better in-
formed about her medical condition (Y). Key reported
motives to participation for the 9 non-participants were
a negative association or dislike of one of the interven-
tions, either because it might do harm (C, D, E, G, I, K)
or for practical reasons associated with the intervention
(A, B, O). “Women also described first-time pregnancy or
being in an exceptional situation as playing a role.”, or she
was already in an exceptional situation, like a twin preg-
nancy or a pregnancy after intrauterine insemination.
Themes identified as related to the decision on trial
participation
During the open coding we identified 47 sub-codes,
based on phrases relating to barriers and facilitators.
These were grouped into 13 categories, and further
grouped into seven main themes (Table 4), discussed
below.
A. External influence
Women indicated that they discussed the invitation to
enroll in a trial with their partner, where the partners
opinion influenced the decision on whether to partici-
pate or not. This influence could be either positive or
negative, giving the women more confidence to decide
to participate or withholding her from participation if
the partner perceived more risks of participation. In two
cases the woman and her partner disagreed. Women in-
dicated that opinions of persons other than their partner
were not very influential.
“I did discuss it with my husband. Myself, I already
thought, like, I’m fine with it. My attitude did depend
on what my husband would say, too, but he said
something like: that’s good. So we agreed. Interviewer:
“And if he [your partner] hadn’t agreed?” Participant:
“Then I wouldn’t have done it.” [Participant Allo trial]
Table 2 Characteristics of the women included
Code Ethnicity Level of education Age Study Paritya
Participants
J Dutch Intermediate/low 30-34 Allo Nulliparous
L Dutch Higher education 35-39 Allo Parous
M Dutch Higher education 30-34 Allo Parous
N Dutch Higher education 25-29 Apostel I Parous
P Dutch Higher education 25-29 Ppromexil Nulliparous
Q Dutch Intermediate/low 25-29 Ppromexil Nulliparous
T Dutch Higher education 30-34 Hypitat II Parous
U Dutch Higher education 35-39 ProTWIN Nulliparous
V Non-Dutch Higher education 35-39 Hypitat II Parous
W Dutch Higher education 35-39 Apostel II Parous
Y Non-Dutch Higher education 35-39 CHIPS Parous
Z Non-Dutch Higher education 25-29 WOMB Parous
Non-participants
A Dutch Higher education 35-39 WOMB Parous
B Dutch Unknown 25-29 ProTWIN Nulliparous
C Dutch Higher education 30-34 ProTWIN Parous
D Non-Dutch Higher education 30-34 ProTWIN Parous
E Non-Dutch Higher education 35-39 Hypitat II Parous
G Dutch Higher education 25-29 Apostel II Nulliparous
I Dutch Higher education 20-24 ProTWIN Nulliparous
K Dutch Intermediate/low 20-24 Ppromexil Parous
O Dutch Intermediate/low 20-24 Hypitat II Nulliparous
aParity was registered at the time of the interview
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Table 3 Main motives for participation or non-participation as answered to the starting (open) question
Code Citation
J “I don’t think research is ever actually bad, and this is not a study where they do real experiments, so it’s always good to learn from it for
someone else.”
L “Actually, in our first pregnancy our daughter was in foetal distress and so we had to have a caesarean section. This might have been an
option then, too, as it has something to do with foetal distress, then administering this. And my husband actually asked more questions:
does it have drawbacks for the child? No? Then we’ll join, because the study is necessary.
There’s also my medical background. I’ve worked on maternity wards, too. When you work in medicine, you’re open to innovation and new
techniques.”
T “Two things, actually. In my first pregnancy I had pre-eclampsia, so I was very well aware what the consequences might be for me, and then
also for the child… Personally, I support the aims of the study, to let you have your baby from 34 weeks onwards, because the risks do not
outweigh for mother and child, so to speak. Second, I’ve been coming to a teaching hospital for years, for other treatments as well, and I
believe very much in the academic side. I believe in development and trying new things. And, well, research is part of that because if you
never do any studies, you can never do anything new.”
U “Well, originally I was invited to take part in a study about the pessary, a study of twins. I thought: seems good to me, I have a twin sister
myself and I used ICSI to conceive, so there were also people who took part in this kind of study for me. That’s how I’m pregnant now.”
Z “Well, first, it did really apply to me and there was the choice between taking blood or iron. Otherwise it would have been iron, whatever. So I
thought, let’s see what happens with this. And I was in the blood group. Looking back, I’m very happy with it. And, as I just said, I often do
studies myself. So then you know better how important it is, that you need to recruit people, so erh, actually that’s the only reason.”
M ”The most decisive factor, of course, is that the consequences of oxygen deprivation are pretty severe. If you could reduce that in some way,
by taking a particular drug, then I’d choose it. Yes, yes, good. And because the drug was already being used for other things – OK, so it hadn’t
yet been fully tested for oxygen deprivation – then it shouldn’t have any bad effects. You assume that it can only be beneficial. And so then
I think, like, that’s something I want to take part in.”
P “OK, well, that was mainly due to the fact that there was a chance that my labour would be induced, otherwise I’d have to wait until
37 weeks come what may… The contribution to research as well, of course, I thought that was a good cause, but it wasn’t the most
important. I thought: I’m going for immediate induction. I couldn’t imagine having to stay in hospital for five days, not allowed to do
anything, so I thought, like, let it come now.”
Q “First of all, I don’t see myself lying here for another five weeks. And pretty soon after that the realisation that you’re already open down there,
with a risk of infection for yourself and for the baby. And yes, in Enschede the doctors also said it was viable enough, so that was for us a
reason to take part.”
V “That once the baby was out my high blood pressure would be gone. That’s what I thought, that was about it. But on the other hand, I was a
bit scared. Will I have him earlier – that was at 36 weeks – so it was a bit of a dilemma deciding what would be best. Then she explained to
me: the earlier the baby’s out, the better it should be for mother and child. So that was actually the reason why I said I’d do it.”
W “That was because I hoped it would be better for the baby, although I still had an uneasy feeling about it. That was because nobody could
say what the potential adverse effects were. Yes, I kept on feeling uneasy about it.”
“And I had something like, in my case it can only be positive, because I mean, the test would indicate whether the chance was very high that
you would deliver very soon, or that it could take a while. So, I really felt like, I felt that I ran little risk, because if the test would show that you
would fall into the test group, than you would get either a placebo or tocolytics.”
N “And I thought something like, in my case it can only be positive because, I mean, the test would indicate whether the chance was very high
that you would deliver very soon, or that it could take a while. So I really felt like I wasn’t running much risk, because if the test showed that
you fell into the test group, then you would get either a placebo or tocolytics.”
Y “Then you know how and what.”
C “Well, there were several reasons actually. When your colleague started talking about it, when I had an appointment about it, I thought: ‘Oh
my God, no, not a pessary! Because I had a friend who was admitted to hospital because a pessary [not in pregnancy] had caused a lot of
bleeding. So that’s what I told her [the colleague]: that that had been a life threatening situation. So I had a feeling of, like, if I think now
about pregnancy and a pessary, it doesn’t make me very happy.”
D “For me it was pretty clear, actually. Once I was here I thought, like, just let Mother Nature do her work. I’m pretty religious [Muslim], so
perhaps there’s a reason why those children are born early. I believe in God, you know. I think, like, fate decides. If those children want to be
born earlier, then so be it. If not, then not. That was my thinking. I was scared, too. What if I take part and something happens to me, a bit of
blood loss – or a lot – or something happens to the babies.”
E “She [baby] was four weeks early and that blood pressure kept on rising. They just couldn’t get it down. I’d already been lying there for a
month and I’d had enough. You want something to happen. Then they asked me: do you want to take part in this study? Because there’d
come a point when the doctors were saying, we don’t know any more, either. So I thought, well, if they don’t know, who does? I had to
make my own choice. … And then I thought, actually I can better prolong it for a while, to see how long it takes. Because if I had decided to
take part, you don’t know whether you’ll be induced or not. That’s not certain, either. So then the disappointment can be huge. That was
when I decided not to do it, to see how long we could prolong it.”
G “I had a very tough pregnancy, with a lot of bleeding, and in fact the whole nine months were entirely uncertain… I was given those lung
development injections and I tocolytics, after which I couldn’t feel my baby at all… When they asked if I wanted stay on the tocolytics,
I linked them a bit with that so I thought, like, no – because I wanted to feel my baby again as soon as possible, to regain a bit of the
certainty that everything was alright. So for me, that was the most important reason.”
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Women indicated they had decided on participation
without consulting their gynecologist, however when the
gynecologist was contacted, his or her opinion was in
most cases influential. All respondents felt free to make
their own decision, without feeling pressure from anyone
to participate.
B. (Contribution to) research and healthcare
Contribution to scientific research was a reason for par-
ticipation, as they were convinced about its importance.
“And I also looked at it like this: these are studies for
the future, and after all I have a daughter and you
never know. In that case I’m the kind of person to
take part in things for other people, so that it’s better
in the future than it is now, for example. What other
people have done in the past, I’m making use of now.”
[Participant Hypitat II trial]
Interviewees who had declined participation judged
scientific research also important, but other themes
outweighed this importance. One participant suggested
to improve publicity on clinical trials and research in
pregnancy:
“Maybe they should be a bit more up-front about
saying, if people are pregnant anyway, that there are
studies that people can take part it. Maybe that it’s
passed on to people in some way or another as soon
as they fall pregnant, so that you know about it. I
didn’t think about it. I’ve never experienced this
before. I think that would cause less stress. Say you
get leaflets in advance, “scientific research for
Table 3 Main motives for participation or non-participation as answered to the starting (open) question (Continued)
I “At first I was really inclined to participate, because a lot of people close to me said, just say it works. Your babies will stay inside longer. But
personally, I had the feeling that everything was going very well, that it all, yes… And I do react quite strongly to things, to jewellery or a
piercing or something. So I think, if something’s going to be stuck inside my body, it might react really badly. If nothing’s wrong and I do
that… I found that a bit scary. And then there’s the fact that you couldn’t choose which group you were in. That’s logical with a study, but
that’s why I didn’t do it in the end.”
K “Well, it’s not without a reason that they tell you that you’re officially allowed to deliver from 37 weeks on, so yes, I thought it was a risk being
induced at 34 weeks. Because the doctors don’t just say: from 37 weeks the doctors will induce you automatically and they’re doing a study
and I didn’t want to be a guinea pig. If something then goes wrong …”
A “I would happily have taken part if I could have opted for iron tablets, but that choice wasn’t available. You have to participate blind, and
then I don’t know who decides. I don’t know how that works, but someone else decides for you which of the two you are going to do.
What’s also complicated: I didn’t want a blood transfusion. I was lying there on a drip and I had a catheter, and then I thought that with iron
tablets I could go home and otherwise I would have to stay even longer.”
B “I’m at the AMC. That’s a teaching hospital and they do all kinds of research there. I would have to come in more often – it was all about a
pessary against premature birth – and I would have to come in more often to measure it up and for ultrasound. I did seriously consider it, but
those extra visits… If was in pain, for example, or it wasn’t convenient. And I’d just heard I was pregnant with twins sharing an amniotic sac,
which is a very rare situation – you have a lot information coming at you.”
O [Unplanned pregnancy] “Yes, and everything suddenly went so fast. Then I really thought, like, well, I don’t have to be induced tomorrow.
That… the chance was 50%, and I didn’t need that. No, I feel it’s all gone too fast. Because you’re… No… After three weeks attending the
hospital, I was admitted. I’d never been in hospital before and… Yes, yes, I was homesick. Yes. But, I didn’t think, like, whip him out tomorrow.
Really, that just wasn’t what I wanted. That was simply too fast for me. I couldn’t take it all in.”
Table 4 Seven main themes that influences trial participation
Theme Sub codes
External influence ▪ Concern from social environment
▪ Trust in the health professional
▪ Feeling of disappointing the health
professional
Research and healthcare ▪ Familiarity with scientific research
▪ Willingness to contribute to research
▪ Feeling of participating in an experiment
Perception own situation ▪ Perception own situation and medical
history
▪ Feeling very eligible or very ineligible for
scientific research




▪ Insurance medical research
Intervention ▪ Intervention
▪ Natural course
Information and counseling ▪ Written information
▪ Counseling: information and timing,
atmosphere




▪ Physician does not know what is best
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pregnant women”, and you’ve read them. Then you
know already that it might come up. You can already
think about it.” [Participant Ppromexil study]
C. Perception own situation
The perception of one’s own situation appeared influential
in the decision on participation: women considered them-
selves either very eligible or not at all eligible for scientific
research, sometimes taking into account their current com-
plicated pregnancy, medical history or their own nature.
“There are people who do that [participate in trials],
and that’s all very wonderful and good, but I’m not
that kind of person. You know, no playing about my
body. Maybe if it was just one [baby], but now it’s
already scary and if there’s going to be all that fiddling
with your body, then give me the natural way.”
[Non-participant ProTwin]
Intuitional or emotional elements were also reported.
When asked whether their decision was rational, some
women answered they trusted their feelings, or were in-
clined to participate but did not participate because it
did not feel good.
D. Study design
Randomization was perceived negative and resulted in un-
certainty. Women could not explain (in any way) why
randomization was used, or could be used. This seemed
based on a combination of not knowing why rando-
mization could or should be used, and not trusting that
there is really equipoise and the doctor does not know
what is best for them. This seemed based on a com-
bination of not knowing why randomization could or
should be used, and not trusting that there is really equi-
poise and the doctor does not know what is best for them.
In the Netherlands, when explaining randomization as
‘loten’ a Dutch word meaning drawing straws that has the
connotation of faith or destiny, this was perceived nega-
tive, while explaining randomization by means of a com-
puter selecting a group for the participant, this was
considered more positive. Therefore Dutch doctors should
avoid this.” However this lack of knowledge was not ne-
cessarily a barrier for participation.
“Because if I had decided to take part, then are you
going to be induced or not? That’s also a doubt. So
then the disappointment is huge. No, the uncertainty;
[if you decide for yourself,] you go in and you know
where you’re going.” [Non-participant HYPITAT II]
E. Intervention
Participants mentioned the potential therapeutic benefit
of the intervention as a reason for participation.
“Well, yes, if they stay inside longer in that case, than
that’s an advantage for me, too. Actually, that was
my only reason for taking part. But I did need to be
convinced that there wouldn’t be any drawbacks if
they didn’t stay inside so long because of it.”
[Participant ProTwin trial]
Other women disliked an interventional (“active”)
strategy, and rather preferred the natural course, or were
more focused on potential (unknown) negative effects.
They mentioned that the risk associated with a natural
course is one you do not choose for. It is already pre-
sent, contrary to the risk of an intervention or the risk
of trial participation, which result from the women’s
choice. All non-participants stated that a negative as-
sociation with the intervention or a negative effect of
intervention played a role, as discussed under the main
motivations.
“To me it was already pretty clear, actually. Once I
was here I thought, like, just let Mother Nature do
her work. I’m not going to mess around with with
something if nature has decided that’s the way it is.
I let it be, you know.” [Non-participant ProTwin trial]
F. Information and counseling
Women considered the information adequate, but indi-
cated that the counseling was done very hastily. A no
rush atmosphere, where counseling was often done by a
research nurse or midwife, with sufficient time to discuss
questions, was viewed as positive.
“But maybe with hindsight I think it matters a lot: the
person who comes to tell you [about the study]. If
someone like Ms J [the research midwife] had come
to my bed at the beginning and taken her time over it,
then maybe I would’ve thought differently than when
you have a doctor perched on the window-sill, only
just not looking at her watch, saying I’m just popping
in for five minutes and then I’m gone and you have to
make a decision. Because you have to join the study at
two o’clock this afternoon, otherwise it’s too late. Yes,
that feels different and the results are different.
Perhaps even when it comes to taking part in the
research.” [Participant Apostel II]
One women said she had received unclear and incom-
plete written information, but nonetheless she participated.
“These are the same tocolytics you normally get,
they’re no different. It’s not a new drug, but I only
realised that later. It wasn’t made clear at the time I
had to decide. It looked like it was a new drug, or a
new way of seeing whether it can be kept inside
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longer if your waters break early, and what harm that
could do to the child or the mother. In other words,
in the future, when people come in with waters that
have broken early, can we give them these pills with
confidence? That was my feeling about the study,
actually, and when I had to say yes I didn’t know that
it was the same drug and what harmful effects it
might have. If that was all explained very clearly then,
including the harmful effects it might have – that’s
the research, of course – then I’d join more easily. If
they can say that the only harmful effect is that he’ll a
bit smaller or a bit bigger, or a bit more to the left or
a bit more to the right… But if you don’t know that,
then it’s pretty difficult. It’s a whole ethical issue.”
[Participant Apostel II]
Women felt the time to consider participation was ad-
equate, or they understood why the time for consider-
ation was short, except one woman. Some women
declined participation because there was an overwhelm-
ing amount of new information, or timing was not right.
G. Uncertainty
The theme uncertainty emerged in interviews of both
participants and non-participants. Non-participants expli-
citly mentioned to have declined participation because of
feelings of uncertainty. This prevailed over other factors
even before they had reached the stage of explicitly weigh-
ing the advantages and disadvantages of participation
“No, I didn’t consider that at all, actually. I didn’t
think about it. For me the safety of the baby had to
come first. No, I didn’t see any benefit in it. No, they
[the doctor/counsellor] didn’t bring up the advantages
side and I didn’t ask about it.” [Non-participant
Ppromexil trial]
In both groups women indicated that being confronted
with an (unexpected) invitation to participate in scientific
research was stressful and needed thorough consideration.
“I don’t know if it’s really stressful, but we have
talked about it a lot. You know, with my husband
and also with a friend of mine in Rotterdam. And I
have been very busy with it in my head, but whether
it’s caused physical stress? I don’t know. Yes, I have
thought a lot about it, because you can never be
right. If he’d been born and there was something
wrong and I hadn’t taken part in the study, then I
would’ve thought: if only I had taken part in the
study. And if he’d been born and I had taken part
and there was something wrong, then I’d have
thought: if only I hadn’t taken part in the study.”
[Participant Apostel II]
Some women were really surprised when confronted
with the fact that ‘2010 state of the art health profes-
sionals’ do not always know what treatment is best.
“They [the doctors] also said, ‘We think it’s a very silly
thing to say, and very strange for you, but we have to
be honest: we don’t know. And I was lying all the
time, thinking ‘I’ll see what happens’. Until that
moment, when I thought, well, actually I felt I’d been
left to my fate. You’re not lying there for nothing.
They know it, they’ve studied for this. I’m sure they
could tell me what direction it’s best to go in, but
apparently they can’t. And that’s really tough. They
could only give you certain facts. Well, not even that,
really, just that research was there for a reason.”
[non-participant Hypitat II]
Discussion
Contributing to scientific research was for many partici-
pants their main motive for participation in the trial,
while others were motivated to participate because the
intervention seemed favorable and was not available out-
side the trial. Key motives for non-participation were a
negative feeling towards the intervention, either because
it might do harm, or for practical reasons. We identified
seven themes that influenced the decision to participate in
a trial. We noted that uncertainty about scientific research
or the intervention was of considerable importance.
This study examined a variety of trials, which were not
selected based on their recruitment performance. We
sampled patients from multiple trials, multiple centers,
invited to enroll by various health professionals, in dif-
ferent geographical areas in the Netherlands. The re-
sponse rate was high. More non-participants declined an
interview, however only two of eleven non-participants
invited by phone declined to be interviewed. All inter-
viewees stated that the counseling and the decision mak-
ing process were very well remembered, which was
confirmed by the interviewer. Therefore, we think this
did not very much influence the reported barriers and
motivators. The varying settings of the interview – either
at home or in the hospital – could have influenced the
results. As we left the choice for the setting to the inter-
viewee, we think the interviewee had chosen the setting
where he or she felt most comfortable to talk about their
decision. Most interviews were at the woman’s home.
We felt the setting did not restrict women to talk openly
about their motives for or barriers to trial participation.
A potential limitation of qualitative research is the
introduction of bias, as interpretation is an inevitable
part of the analysis of the transcripts. We therefore re-
lied on two researchers to examine the transcripts. An-
other limitation is the relatively small sample, were we
included a high rate of women with higher education.
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However, views of women with lower or intermediate
education were represented. Moreover, in the group of
participants more women seem to be multiparous and
older than in the non-participants group. A possible ex-
planation for this, is because they are more familiar to
being pregnant and they already delivered before, and
therefore multiparous women more often participated.
However, given the small sample we cannot exclude that
these differences are due to chance.
We considered the sampling of women over multiple
studies as a strong point of our study, improving ge-
neralizability, but given the small sample it is difficult to
determine the effect of the sampling from the different
studies on the reported barriers and facilitators. This has
affected the relative importance of the different barriers
and motivators, but this study was designed to get an
overview of the main aims for participation or non-
participation in trials.
We considered data saturation reached, defined as no
new information emerging during the last two inter-
views. However, the interpretation of data being satu-
rated could be argued. As we sampled from different
studies, we considered ‘distrust in the intervention’ as a
motive, whether this was a pessary in the ProTwin study
or iron tablets in the Womb study. We think this was
adequate for getting an overview of the reasons to par-
ticipate or not participate, but adding more studies
might lead to more variety within the motive ‘distrust in
the intervention’. In order to quantify or to determine
the magnitude of the results in the total population, a
larger cross-sectional survey in a representative group of
women should be done.
The seven themes identified in this study have been re-
ported previously. Kenyon et al. conducted interviews with
women who had participated in the ORACLE study, a ran-
domized trial investigating the value of administration of
antibiotics during premature labor. They concluded that
women gave prominence to the socio-emotional aspects of
their interactions with healthcare professionals in making
decisions on trial participation. The interviews suggested
that the stressful situation (of being asked to participate in
a trial) affected their ability to absorb the information. The
main motivation for trial participation was the possibility
of an improved outcome for the baby. Another important
motivation was an opportunity to help others, but this was
conditional on there being no risks associated with trial
participation [19]. McCann and colleagues introduced the
term ‘conditional altruism’, which describes that the will-
ingness to help others initially inclines people to partici-
pate in a trial, but is unlikely to actually lead to trial
participation unless people also recognize that participa-
tion will benefit them personally [20].
Uncertainty due to unfamiliarity with research or re-
search methods was also identified as a theme related to
trial participation in pregnant women [6, 21], and in a
systematic review not restricted to pregnant women
[21]. Unfamiliarity with randomization was a reason for
uncertainty; for many patients it remained unclear why
randomization is used. Robinson and colleagues investi-
gated lay public’s understanding of equipoise and ran-
domization in hypothetical randomized trials [22]. Even
participants who could correctly explain the rationale
behind random allocation doubted the possibility of
equipoise and saw no benefits of random allocation over
the doctor/patient choice. They concluded that, given
the extent of disparity between the assumptions under-
lying trial design and the assumptions held by the lay
public, the solution is unlikely to be simple.
Some women reported that they would let mother
Nature do her work. They were reluctant to actively
choose for an intervention in an (perceived) uncomplicated
pregnancy. Lyerly at all reported that women focused on
risks associated with medical interventions during preg-
nancy, not taking into account the demonstrable risk to
both woman and fetus of not intervening [23].
Many women were surprised to learn that the doctor
does not always know what is best. This was also reported
by Mohanna: ‘Some patients will prefer to assume that
[My] doctor knows best [about me and my baby], and are
not happy to enter into the discussion of uncertainty that
a trial and the issue of informed consent will raise’ [24].
Counseling by research staff, instead of by the treating
physician, seemed to influence participation positively,
which has also been suggested in the review by Tooher
and collegues [7].
To reduce feelings of uncertainty and stress, further
research could elaborate on the work by Junghans and
colleagues, where an opt-out design for low-risk inter-
ventions was proposed [25, 26]. This could not only
increase participation rates, leading to a more represen-
tative study group, but might also shift the responsibility
and difficult decision process from pregnant women to
the health professionals. Ethical committees could or
should be responsible for identifying low-risk trials eli-
gible to run in this system. Patients could for example
be informed about this general policy of opt-out consent
when entering the hospital, invited to sign a general in-
formed consent about the use of data to improve
quality.
Alternatively, one could think of a trial risk classifica-
tion system, where the potential risks of a trial are com-
municated with uniform labels, much like energy labels,
to make them more transparent for patients. An “A”
classification for example could mean that widely used
interventions are compared, with no additional risk
compared to usual clinical practice. A classification of
“E” could mean that the new intervention being tested is
highly experimental. One could imagine that health
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professionals generally recommend participation in all
“A” trials, instead of explicitly leaving the choice to the
patient.
Uncertainty could also be reduced, and awareness im-
proved, if pregnant women became more familiar with
scientific research in general, and studies in pregnancy
specifically. This calls for a national public campaign. In
2008 the ‘Get Randomized’ campaign was launched in
the UK, informing the public about the importance of
clinical trials using television, radio and newspaper ad-
vertising. The campaign increased public awareness of
clinical trials, but those who did recall the ads were not
more inclined to personally take part in a clinical trials if
invited, than those who did not remember [27]. In the
United States a comparable campaign celebrating the
‘everyday medical heroes’ of clinical research has been
established. Its initiators believe the public has a poor and
often negative understanding of clinical research [28].
For trials in pregnancy, general information leaflets,
available when entering a midwifery practice or a hos-
pital, could introduce the goals, methods and necessity
of scientific research. Health professionals could discuss
trial participation in general, and trials in pregnancy in
specific, early in a pregnancy. Or a national public cam-
paign that raises awareness and reduces barriers to par-
ticipation in trials could be considered. All this could
habituate women more to scientific research and the
methods used in it.
Conclusion
We identified seven themes that influenced the decision
to participate in a trial. Contributing to scientific research
was for many participants their main motive for participa-
tion in the trial, while others were motivated because the
intervention seemed favorable and was not available out-
side the trial. Key motives for non-participation were a
negative feeling towards the intervention, either because it
might do harm, or for practical reasons. We noted that
uncertainty about scientific research or the intervention
was of considerable importance.
Measures should be taken to habituate pregnant
women more to scientific research and the methods
used in it. Without pregnant womens’ contribution and
participation, we would not be able to advance our un-
derstanding of the effectiveness of interventions in preg-
nancy and childbirth.
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